Total Testosterone: What Your Number Changes About Your Treatment

What Total Testosterone Actually Measures

Total testosterone captures every molecule of the hormone circulating in your blood, both the fraction bound to sex hormone-binding globulin (SHBG) and albumin and the small percentage (2% to 3%) that floats free. A single number, reported in nanograms per deciliter, represents the sum of all three pools. The distinction matters because SHBG-bound testosterone is biologically inactive. It cannot enter cells or activate androgen receptors.

The Endocrine Society's 2018 clinical practice guideline recommends measuring total testosterone first, then refining with free or bioavailable testosterone only when SHBG abnormalities are suspected [1]. Conditions that raise SHBG (aging, liver disease, hyperthyroidism, anticonvulsant use) can push total testosterone into the normal range while bioavailable testosterone is genuinely low. Conditions that suppress SHBG (obesity, type 2 diabetes, nephrotic syndrome) do the opposite.

This is why the test is drawn in the morning. Testosterone follows a circadian rhythm, peaking between 7:00 and 10:00 AM and declining as much as 35% by late afternoon [2]. A blood draw at 3:00 PM can classify a man as hypogonadal when his morning value would have been perfectly normal. The American Urological Association specifies that samples collected after 10:00 AM should be interpreted with caution [3].

Two abnormal morning values are required before a clinician can assign the diagnosis. A single low reading is not enough.

The Diagnostic Threshold That Opens (or Closes) the TRT Door

The number 300 ng/dL functions as a clinical gate. Below it, on two confirmed morning draws with symptoms present, a man meets the Endocrine Society's definition of hypogonadism and becomes a candidate for testosterone replacement [1]. Above it, the same symptoms (fatigue, low libido, depressed mood) are attributed to other causes and TRT is generally not initiated.

That threshold is not arbitrary. It derives from the lower limit of the reference range established by the CDC's Hormone Standardization Project (HoSt), which used liquid chromatography-tandem mass spectrometry (LC-MS/MS) across a cohort of 9,054 non-obese men aged 19 to 39 [4]. The resulting reference interval was 264 to 916 ng/dL, and guidelines rounded up to 300 ng/dL as the practical cutoff.

A man with a total testosterone of 310 ng/dL and classic symptoms sits in a gray zone. The AACE 2020 position statement acknowledges that "symptoms may occur at testosterone levels within the lower quartile of the normal range" and recommends checking free testosterone or bioavailable testosterone in these borderline cases [5]. If free testosterone falls below 5 ng/dL, treatment may still be appropriate.

The clinical reality: your number does not just tell your doctor you are low. It determines whether insurance will cover your prescription, whether a pharmacy will fill it, and whether your clinician faces regulatory scrutiny.

How Your Baseline Number Shapes the Starting Prescription

Clinicians do not hand every hypogonadal man the same prescription. The starting formulation, dose, and monitoring schedule all shift based on how far below threshold your total testosterone falls.

A man presenting at 180 ng/dL with severe fatigue and erectile dysfunction receives a different approach than a man at 280 ng/dL with mild mood changes. The Endocrine Society guideline recommends starting injectable testosterone cypionate at 75 to 100 mg weekly (or 150 to 200 mg every two weeks) for most men [1]. Topical gels (1% or 1.62% testosterone) are an alternative when patients prefer daily application or when more stable serum levels are desired.

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society guideline, has stated: "We target a mid-normal testosterone level, typically 450 to 600 ng/dL at trough, because supraphysiologic levels increase erythrocytosis risk without additional symptomatic benefit" [1].

For men with very low baseline values (<150 ng/dL), clinicians often prefer injectables over gels because transdermal absorption varies widely. Studies show that up to 30% of men on topical testosterone fail to reach target levels, a problem less common with intramuscular or subcutaneous injections [6]. A baseline total testosterone below 150 ng/dL also prompts evaluation for secondary causes (pituitary adenoma, Kallmann syndrome, opioid-induced hypogonadism) before starting replacement.

Nasal testosterone (Natesto) and subcutaneous pellets (Testopel) occupy narrower prescribing lanes. Natesto, dosed at 5.5 mg per nostril three times daily, preserves spermatogenesis better than injectables but produces more modest testosterone elevations [7]. Pellets deliver 150 to 450 mg implanted every 3 to 6 months and suit men who want minimal day-to-day management, though dose adjustments are less flexible.

Mid-Treatment Monitoring: When the Number Triggers a Dose Change

Once TRT begins, your total testosterone at the 3-month mark tells the clinician whether the current dose is working, falling short, or overshooting. The monitoring protocol follows a predictable decision tree.

If trough total testosterone sits between 450 and 600 ng/dL and symptoms have improved, the dose stays. If the trough remains below 300 ng/dL despite adherence, the clinician increases the dose or switches formulations. If total testosterone exceeds 900 to 1,000 ng/dL, the dose is reduced. These are not suggestions. They are the Endocrine Society's explicit monitoring recommendations [1].

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, provided the largest safety dataset for TRT monitoring [8]. Men randomized to transdermal testosterone 1.62% gel were titrated to maintain total testosterone between 350 and 750 ng/dL. The trial found no increase in major adverse cardiovascular events (HR 0.96, 95% CI 0.78 to 1.17) at a median follow-up of 33 months, but it reinforced the importance of staying within the physiologic range [8].

Hematocrit is the safety valve. TRT stimulates erythropoiesis, and the Endocrine Society recommends checking hematocrit at baseline, 3 months, and annually [1]. If hematocrit exceeds 54%, the clinician must reduce the dose or suspend treatment until levels normalize. In TRAVERSE, the incidence of polycythemia (hematocrit >54%) was 3.5% in the testosterone group versus 0.4% in the placebo arm [8].

PSA also enters the monitoring equation. A confirmed PSA rise greater than 1.4 ng/mL within any 12-month period, or a velocity exceeding 0.4 ng/mL per year, warrants urological evaluation before continuing therapy [1].

What Happens When Total Testosterone Is Too High

Supraphysiologic total testosterone (above 1,000 to 1,200 ng/dL on replacement) is not a marker of success. It is a signal to cut the dose. Elevated levels carry concrete clinical consequences.

Polycythemia is the most immediate concern. Every 100 ng/dL increase in total testosterone above the physiologic range raises hematocrit approximately 0.5% to 1.0% [9]. Thickened blood increases venous thromboembolism risk. The FDA's 2015 label revision for all testosterone products added warnings about blood clots in veins and arteries [10].

Excess testosterone also aromatizes to estradiol. When estradiol climbs above 40 to 50 pg/mL, men may experience gynecomastia, water retention, and mood instability. The fix is dose reduction, not the reflexive addition of an aromatase inhibitor, per the Endocrine Society's recommendation against routine AI use in TRT [1].

Sleep apnea risk increases with supraphysiologic dosing. Testosterone affects central ventilatory drive, and the AACE lists untreated severe obstructive sleep apnea as a relative contraindication to TRT initiation [5]. If a man on treatment develops new snoring, apneic episodes, or excessive daytime sleepiness, polysomnography is indicated.

Testicular atrophy and suppressed spermatogenesis are expected physiologic consequences of exogenous testosterone, not side effects unique to supraphysiologic levels. But higher doses accelerate the suppression of gonadotropins (LH and FSH), making fertility recovery more difficult if therapy is discontinued [11].

The Female Context: Total Testosterone in Women

Total testosterone matters in women's health too, though the thresholds and clinical implications differ entirely. The reference range for adult premenopausal women is approximately 15 to 70 ng/dL, with free testosterone between 0.5 and 3.5 pg/mL [12].

Elevated total testosterone in women triggers a different diagnostic workup: polycystic ovary syndrome (PCOS), congenital adrenal hyperplasia, androgen-secreting tumors, or Cushing syndrome. The Endocrine Society's 2018 PCOS guideline uses total testosterone above the upper limit of the assay-specific female reference range as one criterion for hyperandrogenism, alongside clinical signs like hirsutism and acne [13].

For women with hypoactive sexual desire disorder (HSDD), the International Society for the Study of Women's Sexual Health published a global consensus position in 2019 recommending transdermal testosterone at doses approximating 300 mcg daily, targeting premenopausal physiologic levels [14]. Dr. Susan Davis, a professor of women's health at Monash University, stated: "There is no blood level of testosterone that can diagnose HSDD, but treatment with transdermal testosterone at physiological doses has consistent evidence of benefit in postmenopausal women" [14].

Total testosterone monitoring in women on testosterone therapy follows a different cadence: baseline, 3 to 6 weeks after initiation, and every 6 months, with treatment suspended if total testosterone exceeds the premenopausal reference range [14].

How to Raise Total Testosterone Without (or Before) TRT

For men with borderline-low total testosterone (250 to 350 ng/dL), non-pharmacologic interventions can raise levels enough to delay or avoid TRT.

Weight loss produces the most measurable effect. A meta-analysis published in JAMA Internal Medicine (2022) found that weight loss through lifestyle modification increased total testosterone by a mean of 2.93 nmol/L (approximately 84 ng/dL) per 10% reduction in body weight [15]. The mechanism is straightforward: adipose tissue expresses aromatase, which converts testosterone to estradiol. Less fat means less aromatization.

Resistance training raises total testosterone acutely and, with consistent training over 12 weeks, produces sustained elevations of 15% to 20% in previously sedentary men [16]. Sleep optimization matters too. Restricting sleep to 5 hours per night for one week reduced total testosterone by 10% to 15% in a controlled study of young healthy men [17].

Clomiphene citrate (25 to 50 mg daily or every other day) is an off-label pharmacologic option for men who want to raise testosterone while preserving fertility. By blocking estrogen feedback at the hypothalamus, clomiphene increases LH secretion and endogenous testosterone production. A retrospective cohort study found that clomiphene raised total testosterone from a mean of 228 ng/dL to 612 ng/dL over 3 months [18].

Enclomiphene, the trans-isomer of clomiphene, is under investigation as a more targeted alternative with fewer estrogenic side effects, though it is not yet FDA-approved for this indication.

How to Lower Total Testosterone

Lowering total testosterone is the therapeutic goal in two distinct clinical contexts: androgen deprivation therapy (ADT) for prostate cancer and anti-androgen therapy for transgender women or women with severe hyperandrogenism.

In prostate cancer, GnRH agonists (leuprolide, goserelin) or antagonists (degarelix, relugolix) suppress total testosterone to castrate levels (<50 ng/dL, and ideally <20 ng/dL). The HERO trial (N=934) showed that oral relugolix achieved castrate testosterone levels in 96.7% of men by day 29, compared with 88.8% for leuprolide [19].

For transgender women, the Endocrine Society's 2017 guideline recommends targeting total testosterone below 50 ng/dL using estradiol combined with an anti-androgen (spironolactone 100 to 200 mg daily or cyproterone acetate where available) [20]. Monitoring occurs every 3 months during the first year and every 6 to 12 months thereafter.

In PCOS, the goal is not necessarily to lower total testosterone to a specific number but to manage symptoms. Combined oral contraceptives suppress ovarian androgen production, and spironolactone blocks peripheral androgen action. Total testosterone typically decreases by 30% to 50% on combined therapy [13].

Age-Related Decline: When a Falling Number Is Normal

Total testosterone declines approximately 1% to 2% per year after age 30. The Baltimore Longitudinal Study of Aging documented that roughly 20% of men over 60 and 50% of men over 80 have total testosterone below 300 ng/dL [21]. Whether age-related decline constitutes a treatable condition (sometimes called "late-onset hypogonadism") remains debated.

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in 788 men aged 65 and older with total testosterone <275 ng/dL, found that one year of transdermal testosterone gel improved sexual function (mean score increase of 0.58 on the PDQ-Q4, P<0.001) and physical activity (mean 6-minute walk distance increase of 6.1 meters, P=0.04), but had no effect on vitality as measured by the FACIT-Fatigue scale [22].

The clinical takeaway: age-related decline in total testosterone is real and measurable, but treatment benefit is modest and domain-specific. A 70-year-old man with a total testosterone of 250 ng/dL and no sexual symptoms may not benefit from TRT the same way a 40-year-old at the same level does.

The Endocrine Society does not recommend screening asymptomatic men of any age for low testosterone [1]. The test is indicated only when symptoms are present. Your number triggers treatment only when it aligns with your clinical picture. A total testosterone of 280 ng/dL in a man with no complaints is a lab finding, not a diagnosis.